Clinical trials: Blood Pressure Reduction
- Condition Blood Pressure Reduction
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension
Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months…
- Trial name
- NCT00435162
- Testing
- Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Hypertension
SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
To evaluate the effectiveness of diet management with a losartan based titration regimen versus losartan based titration regimen alone on blood pressure reduction in hypertensive patients.
- Trial name
- NCT00739674
- Testing
- losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]), Low Salt Diet
- Volunteers
- 992 people
- Sponsor
- Organon and Co
Hypertension
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
- Trial name
- VIPER-BP (NCT00902304)
- Testing
- Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care
- Where
- 3 sites in United States, Australia
- Volunteers
- 2,337 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
- Trial name
- NCT00441064
- Testing
- Aliskiren
- Where
- 19 sites in United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Type 2 Diabetes, Hypertension
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
- Trial name
- NCT00654745
- Testing
- Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
- Where
- 21 sites in United States
- Volunteers
- 207 people
- Sponsor
- Daiichi Sankyo
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in…
- Trial name
- NCT00434967
- Testing
- Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg
- Where
- 27 sites in Belgium, Latvia and 4 more
- Volunteers
- 2,207 people
- Sponsor
- AstraZeneca